These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 21069341)

  • 1. Clinical benefit of early phase clinical trial participation for advanced sarcoma patients.
    Jones RL; Olmos D; Thway K; Fisher C; Tunariu N; Postel-Vinay S; Scurr M; de Bono J; Kaye SB; Judson IR
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):423-9. PubMed ID: 21069341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
    Yalcin B; Pamir A; Buyukcelik A; Utkan G; Akbulut H; Demirkazik A; Icli F
    Exp Oncol; 2004 Dec; 26(4):320-5. PubMed ID: 15627067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
    J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
    Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
    Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer.
    Arkenau HT; Brunetto AT; Barriuso J; Olmos D; Eaton D; de Bono J; Judson I; Kaye S
    Oncology; 2009; 76(3):151-6. PubMed ID: 19169046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium.
    Okuno S; Maples WJ; Mahoney MR; Fitch T; Stewart J; Fracasso PM; Kraut M; Ettinger DS; Dawkins F; Erlichman C
    J Clin Oncol; 2005 May; 23(13):3069-73. PubMed ID: 15860865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
    Karavasilis V; Seddon BM; Ashley S; Al-Muderis O; Fisher C; Judson I
    Cancer; 2008 Apr; 112(7):1585-91. PubMed ID: 18278813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma.
    Chugh R; Dunn R; Zalupski MM; Biermann JS; Sondak VK; Mace JR; Leu KM; Chandler WF; Baker LH
    J Clin Oncol; 2005 May; 23(15):3597-604. PubMed ID: 15908670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
    Qiu MZ; Xu F; Wang SS; Luo HY; Wang F; Li FH; Sun XF; Xu GC; Lin TY; Huang HQ; Jiang WQ; Guan ZZ; Xu RH
    Ai Zheng; 2007 Dec; 26(12):1344-9. PubMed ID: 18076798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001).
    Hartmann JT; Mayer F; Schleicher J; Horger M; Huober J; Meisinger I; Pintoffl J; Käfer G; Kanz L; Grünwald V;
    Cancer; 2007 Aug; 110(4):861-6. PubMed ID: 17599772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
    Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.
    Chugh R; Wathen JK; Maki RG; Benjamin RS; Patel SR; Meyers PA; Priebat DA; Reinke DK; Thomas DG; Keohan ML; Samuels BL; Baker LH
    J Clin Oncol; 2009 Jul; 27(19):3148-53. PubMed ID: 19451433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment.
    Garrido-Laguna I; Janku F; Falchook GS; Fu S; Hong DS; Naing A; Aaron J; Wang X; Kies M; Kurzrock R
    Clin Cancer Res; 2010 Aug; 16(15):4031-7. PubMed ID: 20525754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
    Maurel J; López-Pousa A; de Las Peñas R; Fra J; Martín J; Cruz J; Casado A; Poveda A; Martínez-Trufero J; Balañá C; Gómez MA; Cubedo R; Gallego O; Rubio-Viqueira B; Rubió J; Andrés R; Sevilla I; de la Cruz JJ; Del Muro XG; Buesa JM
    J Clin Oncol; 2009 Apr; 27(11):1893-8. PubMed ID: 19273704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias--a study of the Spanish group for research on sarcomas (GEIS).
    Maurel J; Buesa J; López-Pousa A; del Muro XG; Quintana MJ; Martín J; Casado A; Martínez-Trufero J; de Las Peñas R; Balañá C
    J Surg Oncol; 2004 Oct; 88(1):44-9. PubMed ID: 15384088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
    Kushner DM; Webster KD; Belinson JL; Rybicki LA; Kennedy AW; Markman M
    Gynecol Oncol; 2000 Aug; 78(2):221-7. PubMed ID: 10926807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
    Pappo AS; Devidas M; Jenkins J; Rao B; Marcus R; Thomas P; Gebhardt M; Pratt C; Grier HE
    J Clin Oncol; 2005 Jun; 23(18):4031-8. PubMed ID: 15767644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.